Form 4: Avalo Therapeutics Director Gilla Kaplan Granted 20,100 Stock Options

Avalo Therapeutics, Inc. Director Gilla Kaplan was granted 20,100 stock options with an exercise price of $4.47, vesting on the first anniversary of the grant date.

Summary

• Gilla Kaplan, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options.
• The options have an exercise price of $4.47 per share.
• The grant date for these options was June 17, 2025.
• The options vest 100% on the first anniversary of the grant date, which is June 17, 2026, contingent upon Ms. Kaplan's continued service as a director.
• The options expire on June 17, 2035.
• Following this transaction, Ms. Kaplan directly beneficially owns 20,100 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive for aligning interests and is a standard compensation practice, indicating stability in corporate governance.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases above the exercise price.
• This represents a standard form of compensation for board members, indicating continuity in corporate governance practices.

Negatives

• Potential for future dilution if the options are exercised, though this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future performance of Avalo Therapeutics' stock price; if the stock price does not exceed the exercise price of $4.47, the options may expire worthless.

Future Outlook

The stock options are structured to vest on the first anniversary of the grant date, indicating a future milestone for the director's equity compensation.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• This type of equity grant is a standard component of director compensation across publicly traded companies, particularly in the biotech sector, where long-term incentives are crucial.
• While specific comparable companies or projects are not detailed in the filing, the structure (options, vesting over time) is consistent with typical compensation practices for non-employee directors at companies of similar size and stage to Avalo Therapeutics.

Corporate Governance

Related Party Transactions

• The grant of 20,100 stock options to Gilla Kaplan, a Director of Avalo Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director interests with shareholder value creation.

Next Steps

• The stock options are scheduled to vest on June 17, 2026, contingent on the director's continued service.
• The options will remain exercisable until their expiration date of June 17, 2035.

Key Dates

Keywords

Avalo Therapeutics, AVTX, SEC Form 4, Stock Options, Director Compensation, Insider Trading, Equity Grant, Corporate Governance